We found that the T genotype of PvuII (rs2234693) in ESR1 was associated with a better OS and a trend for better DFS than the C genotype in postmenopausal, hormone receptor positive early breast cancer patients treated with adjuvant exemestane alone in the TEAM study. This evidence concerns the gene NR4A1 and breast carcinoma.